Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
JIB
GLOBETECH PUBLISHING

Melanoma Development Depends on the Activity of the RUNX2 Transcription Factor

By BiotechDaily International staff writers
Posted on 28 Apr 2014
Image: Expression of RUNX2 in the nucleus of 1205LU melanoma cells (Photo courtesy of the Rutgers Cancer Institute).
Image: Expression of RUNX2 in the nucleus of 1205LU melanoma cells (Photo courtesy of the Rutgers Cancer Institute).
The transcription factor RUNX2 (runt-related transcription factor 2) has been found to play a critical role in melanomagenesis, the processes leading to development of the skin cancer, melanoma.

The RUNX2 gene is a member of the RUNX family of transcription factors and encodes a nuclear protein with a Runt DNA-binding domain. This protein is essential for osteoblastic differentiation and skeletal morphogenesis and acts as a scaffold for nucleic acids and regulatory factors involved in skeletal gene expression.

Investigators at the Rutgers Cancer Institute (New Brunswick, NJ, USA) examined the role of the RUNX2 transcription factor in melanomagenesis. They reported in the March 31, 2014, online edition of the journal Cancer Letters that the expression of transcriptionally active RUNX2 was increased in melanoma cell lines as compared with normal human melanocytes. Using a melanoma tissue microarray, they showed that RUNX2 levels were higher in melanoma cells as compared with nevic melanocytes.

Genetic silencing of RUNX2 in melanoma cell lines significantly decreased Focal Adhesion Kinase expression and inhibited cell growth, migration, and invasion ability. Furthermore, the pro-hormone cholecalciferol reduced RUNX2 transcriptional activity and decreased migration of melanoma cells, further suggesting a role of RUNX2 in melanoma cell migration.

“Successful efforts to render transcription factors “drugable” by interfering with different aspects of their transcriptional activity make this class of proteins attractive targets for therapy,” said senior author Dr. Karine Cohen-Solal, assistant professor of medicine at the Rutgers Cancer Institute. “Exploring the role of RUNX2 in the development of melanoma is likely to reveal new mechanisms driving melanoma progression and identify a target for novel antimelanoma agents, thereby opening new avenues for the treatment of this disease.”

Related Links:
Rutgers Cancer Institute



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: The five stages of biofilm development: (1) Initial attachment, (2) Irreversible attachment, (3) Maturation I, (4) Maturation II, and (5) Dispersion. Each stage of development in the diagram is paired with a photomicrograph of a developing P. aeruginosa biofilm. All photomicrographs are shown to same scale (Photo courtesy of Wikimedia Commons).

Ionic Liquids Disperse Bacterial Biofilms and Increase Antibiotic Susceptibility

The ionic liquid choline-geranate was shown to effectively eliminate the protective biofilm generated by bacteria such as Salmonella enterica and Pseudomonas aeruginosa and to significantly increase the... Read more

Therapeutics

view channel
Image: Hair follicle (blue) being attacked by T cells (green) (Photo courtesy of Christiano Lab/Columbia University Medical Center).

Hair Restoration Method Clones Patients’ Cells to Grow New Hair Follicles

Researchers have developed of a new hair restoration approach that uses a patient’s cells to grow new hair follicles. In addition, the [US] Food and Drugs Administration (FDA) recently approved a new drug... Read more

Lab Technologies

view channel

Important Immune Cell Regulators’ Response Identified

A new strategy could help accelerate laboratory research and the development of potential therapeutics, including vaccines. The technology may also be used to identify the genes that underlie tumor cell development. There are approximately 40,000 genes in each of the body’s cells, but functions for only approximately... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.